Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors
Shares of Bristol Myers Squibb Co. BMY slid 1.00% to $58.12 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.30% to 6,034.91 and Dow Jones Industrial Average DJIA falling 0.35% to 44,247.83.
Bristol Myers Squibb Announces Dividend Increase
Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62) per share on the $0.10 par value common stock of the company.
Bristol-Myers Squibb Sued for $450 Million Over Drug Acquisition
Bristol-Myers Squibb Co. plotted to rip off investors in a 2016 acquisition through legal gamesmanship aimed at evading a $450 million payment, according to a lawsuit unsealed Tuesday.
Bristol-Myers Squibb: Balancing Stability and Competition with Cautious Optimism
Analyst Evan Seigerman of BMO Capital maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target of
Is Bristol-Myers Squibb Stock a Millionaire Maker?
Bristol-Myers Squibb (NYSE: BMY) is the kind of stock that potentially has a lot to offer to investors looking for wealth-building investments. With that in mind, let's examine this stock's potential as a millionaire maker.
Is Bristol Myers Squibb (BMY) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value,
Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors
The stock's fall snapped a two-day winning streak.
Justice on the Move: The Impact of 'Bristol-Myers Squibb' on FLSA Forum-Shopping
Savvy plaintiffs-side attorneys are leveraging this split to avoid bringing their FLSA collective action where the employer ...
Modern Healthcare8h
These pharma lawsuits could transform 340B
Johnson & Johnson and other pharma companies aim to change how the 340B Drug Pricing Program functions. Courts must rule if ...
BioSpace2h
The Right Fit: What BMS, Intellia Look for in Cell and Gene Therapy Talent
When hiring job candidates to work on cell and gene therapies, companies look for more than just technical skills. Talent ...
Bristol Myers raises quarterly dividend 3.3% to 62c per share
Squibb announced that its Board of Directors has declared a quarterly dividend of 62c per share on the 10c par value common ...
Hosted on MSN1h
Keros Stock Hits Rock Bottom After Pulmonary Hypertension Trial Halt, But Retail Bets On A Rebound
Keros Therapeutics Inc. shares lost over three-quarters of their market capitalization on Thursday, marking an all-time low, ...
Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at ASH 2024 with Long-Term Survival Data and Results from Expanding Pipeline
Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at ASH 2024 with Long-Term Survival Data and Results from Expanding Pipeline ...
BioSpace3d
FDA Action Alert: Ionis, Lexicon, Bristol Myers Squibb and More
Ionis Pharmaceuticals is advancing the investigational RNA-targeted therapy olezarsen for the treatment of familial ...